Literature DB >> 36151295

Perinatal exposure to UDCA prevents neonatal cholestasis in Cyp2c70-/- mice with human-like bile acids.

Hilde D de Vries1,2, Anna Palmiotti3, Rumei Li3, Milaine V Hovingh3, Niels L Mulder3, Martijn Koehorst1, Vincent W Bloks3, Tim van Zutphen2,3, Folkert Kuipers1,3, Jan Freark de Boer4,5.   

Abstract

BACKGROUND: Cyp2c70-/- mice with a human-like bile acid (BA) composition display features of neonatal cholestasis. We assessed whether perinatal ursodeoxycholic acid (UDCA) exposure prevents neonatal cholestasis in Cyp2c70-/- mice and reduces cholangiopathy development later in life.
METHODS: Cyp2c70+/- males were crossed with Cyp2c70+/- females fed either a regular chow diet or a 0.1% UDCA-containing diet during breeding, gestation, and suckling. Cholestasis and liver function parameters were assessed in their Cyp2c70-/- and wild-type offspring at 3 and 8 weeks of age.
RESULTS: Three-week-old Cyp2c70-/- pups showed features of neonatal cholestasis, including elevated plasma BAs and transaminases, which were completely prevented in Cyp2c70-/- pups upon perinatal UDCA exposure. In addition, UDCA administration to the dams corrected altered hepatic gene expression patterns in Cyp2c70-/- pups, reduced markers of fibrogenesis and inflammation, and prevented cholangiocyte proliferation. Yet, these beneficial effects of perinatal UDCA exposure were not retained into adulthood upon discontinuation of treatment.
CONCLUSION: Perinatal exposure of Cyp2c70-/- mice to UDCA has beneficial effects on liver function parameters, supporting a direct role of BA hydrophobicity in the development of neonatal cholestasis in these mice. However, prevention of neonatal cholestasis in Cyp2c70-/- mice has no long-lasting effects on liver pathophysiology. IMPACT: This is the first study showing that perinatal UDCA exposure prevents features of neonatal cholestasis that are observed in mice with a human-like bile acid composition, i.e., Cyp2c70-/- mice. Perinatal UDCA exposure of Cyp2c70-/- pups leads to UDCA enrichment in their circulating bile acid pool and, consequently, to a reduced hydrophobicity of biliary bile acids. Perinatal UDCA exposure of Cyp2c70-/- pups has no long-lasting effects on the development of cholangiopathy after discontinuation of treatment. The results in this study expand current knowledge regarding acute and long-lasting effects of UDCA treatment in early life.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36151295     DOI: 10.1038/s41390-022-02303-5

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.953


  44 in total

Review 1.  Neonatal cholestasis.

Authors:  Frederick J Suchy
Journal:  Pediatr Rev       Date:  2004-11

Review 2.  Neonatal liver physiology.

Authors:  James Grijalva; Khashayar Vakili
Journal:  Semin Pediatr Surg       Date:  2013-10-14       Impact factor: 2.754

Review 3.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.

Authors:  Ulrich Beuers; Michael Trauner; Peter Jansen; Raoul Poupon
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 4.  Regulation of bile acid synthesis.

Authors:  J Y Chiang
Journal:  Front Biosci       Date:  1998-02-15

Review 5.  Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.

Authors:  Ulrich Beuers
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-06

6.  Correlation between fetal and maternal serum bile acid concentrations.

Authors:  C Colombo; A Roda; E Roda; M Buscaglia; C A dell'Agnola; P Filippetti; M Ronchi; F Sereni
Journal:  Pediatr Res       Date:  1985-02       Impact factor: 3.756

7.  Physiologic cholestasis: elevation of the primary serum bile acid concentrations in normal infants.

Authors:  F J Suchy; W F Balistreri; J E Heubi; J E Searcy; R S Levin
Journal:  Gastroenterology       Date:  1981-05       Impact factor: 22.682

Review 8.  Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades.

Authors:  Alan F Hofmann; Lee R Hagey
Journal:  J Lipid Res       Date:  2014-05-17       Impact factor: 5.922

9.  Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation.

Authors:  Qing Xie; Vladimir I Khaoustov; Charles C Chung; Joohyun Sohn; Bhuvaneswari Krishnan; Dorothy E Lewis; Boris Yoffe
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

Review 10.  Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.

Authors:  Gustav Paumgartner; Ulrich Beuers
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.